Saturday, 14 December 2019

WuXi Life Science to acquire WuXi PharmaTech for around $3.3 bn

17 August 2015 | Company results | By BioSpectrum Bureau

WuXi Life Science to acquire WuXi PharmaTech for around $3.3 bn

New WuXi Life Science plans to acquire WuXi PharmaTech

New WuXi Life Science plans to acquire WuXi PharmaTech

Singapore: WuXi PharmaTech, research and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, has entered into a definitive agreement and plan of merger with New WuXi Life Science and its wholly owned subsidiary, WuXi Merger.

New WuXi Life Science will acquire WuXi PharmaTech for cash consideration equal to $5.75 per ordinary share of the company and $46 per American Depositary Share of the company, each representing eight shares or approximately $3.3 billion in aggregate cash consideration.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is APAC region emerging as a leader in assistive technologies?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls